Key result
Early cyclosporin-based immunosuppression and LVAD support led to complete resolution of cardiac dysfunction and LVAD removal in a 26-year-old man with fulminant giant cell myocarditis.
Why the study?
Characterizing definitive clinical outcomes of combined immunotherapy and mechanical circulatory support in fulminant giant cell myocarditis remains challenging, and the autoimmunity associated with its onset is controversial.
Population
A 26-year-old man with fulminant giant cell myocarditis and multiple autoimmune disorders
Design
Case report
Follow-up
6-month period following discharge
Authors
Loading...
May support recovery with early cyclosporin immunosuppression plus LVAD in fulminant giant cell myocarditis; hypothesis-generating and requires prospective validation before practice change.
Case Report (n=1)
Early cyclosporin-based immunosuppression combined with mechanical circulatory support can lead to successful recovery and LVAD explantation in patients with fulminant giant cell myocarditis and multiple autoimmune disorders.
Yagi et al. (2022) conducted a case report in Fulminant giant cell myocarditis (n=1). Cyclosporin-based immunosuppression and LVAD was evaluated on Clinical and histopathological remission. Early cyclosporin-based immunosuppression and LVAD support led to complete resolution of cardiac dysfunction and LVAD removal in a 26-year-old man with fulminant giant cell myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: